AllSci News
Sarepta's siRNA conjugate SRP-1005 enters Phase I for Huntington's disease
Sarepta Therapeutics has registered a first-in-human Phase I trial of SRP-1005 (formerly ARO-HTT), an siRNA conjugate designed to silence the huntingtin...
Abogen's mRNA in vivo bispecific T-cell engager shows early promise in B-cell lymphoma
Abogen presented preliminary Phase I ABO2203 clinical results at the AACR Annual Meeting 2026 in San Diego from a first-in-human dose-escalation study of...
Genprex and UT MD Anderson partner to identify biomarkers for Reqorsa lung cancer gene therapy
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company based in Austin, Texas, announced a new Sponsored Research Agreement (SRA) with The…
Orion Pharma’s Odm-212 secures US FDA Orphan Drug Designation for mesothelioma
Finland-based Orion Pharma announced receipt of orphan drug designation (ODD) from the US FDA for ODM-212, an oral small molecule pan-TEAD inhibitor.…
GSK acquires pulmonary hypertension biotech 35Pharma for USD 950m, gaining HS235 asset
GSK (LSE/NYSE: GSK) has completed the acquisition of Canada-based 35Pharma Inc., a private clinical-stage biopharmaceutical company, for USD 950 million in...
Elicera Therapeutics raises SEK 72.8m in rights issue for clinical trials
Sweden-based Elicera Therapeutics AB (Nasdaq First North Growth Market: ELIC) announced a rights issue of approximately SEK 72.8 million, structured to fund...
Nektar Therapeutics raises USD 250m in underwritten public offering
San Francisco-based Nektar Therapeutics (Nasdaq: NKTR) announced on April 20, 2026, an underwritten public offering of USD 250 million in common stock and...
Nektar's rezpegaldesleukin shows Phase II promise as JAK alternative in hair growth
Nektar Therapeutics (Nasdaq: NKTR) reported that rezpegaldesleukin, its investigational IL-2 pathway agonist, continued to generate new hair growth...
Specialised Therapeutics wins Australia, Singapore approval for Zepzelca with Tecentriq for ES-SCLC maintenance
Specialised Therapeutics has received regulatory approval in Australia and Singapore for Zepzelca (lurbinectedin) in combination with Tecentriq (atezolizumab) as a first-line maintenance…
Roche aiming to add SLE indication for Gazyva after positive Phase III
Roche (SIX: RO; OTCQX: RHHBY) announced that the FDA has accepted its supplemental Biologics License Application for obinutuzumab (Gazyva/Gazyvaro) in...
Arcus, Gilead halt Phase III TIGIT lung cancer trial for futility; collaboration narrows
Arcus Biosciences has discontinued the Phase III STAR-121 trial of TIGIT-targeted domvanalimab in first-line metastatic non-small cell lung cancer (NSCLC) after a…
Immunocore's tebentafusp doubles five-year survival in metastatic uveal melanoma Phase III trial
Immunocore Holdings (Nasdaq: IMCR) reported five-year overall survival data from the Phase III CT029 trial at AACR 2026, showing that tebentafusp (Kimmtrak)...
Sanofi's Nuvaxovid shows significantly better tolerability than Moderna's mNEXSPIKE in Phase IV COVID-19 trial
Sanofi (Nasdaq: SNY) reported that its recombinant protein-based COVID-19 vaccine Nuvaxovid produced statistically significant lower systemic reactogenicity...
Agenus emphasizes positives after Phase II miss in PD-1 refractory gastroesophageal cancer
Agenus Inc. (Nasdaq: AGEN) reported Phase II data from an investigator-initiated trial combining botensilimab, balstilimab, and agenT-797 in PD-1 refractory...
Biogen consolidates global felzartamab rights via USD 850m agreement with TJ Biopharma
Biogen (Nasdaq: BIIB) has entered into a definitive agreement to acquire China-based TJ Biopharma's exclusive rights to felzartamab in the Greater China...
The AllSci Brief
Systematic R&D and deal news. Daily.